Abstract
Monoamine transporters are the main targets of methamphetamine (METH). Recently, we showed that fluoxetine, a selective serotonin reuptake inhibitor (SSRI), decreased METH conditioned place preference (CPP), suggesting that serotonin transporter (SERT) inhibition reduces the rewarding effects of METH. To further test this hypothesis, in the present study we investigated the effects of additional SSRIs, paroxetine and fluvoxamine, on METH CPP in C57BL/6J mice. In the CPP test, pretreatment with 20 mg/kg paroxetine abolished the CPP for METH, whereas pretreatment with 100 mg/kg fluvoxamine prior to administration of METH failed to inhibit METH CPP. These results suggest that paroxetine, a medication widely used to treat depression, may be a useful tool for treating METH dependence. Further, these data suggest that molecules other than the SERT [such as G protein-activated inwardly rectifying K+ (GIRK) channels] whose activities are modulated by paroxetine and fluoxetine, but not by fluvoxamine, are involved in reducing METH CPP by paroxetine and fluoxetine.
Keywords: Conditioned place preference, Fluvoxamine, Methamphetamine, Mice, Paroxetine, Serotonin transporter, dopamine transporter, Knoutout mice, Biochemical Down Regulation
Current Neuropharmacology
Title: The Selective Serotonin Reuptake Inhibitor Paroxetine, but not Fluvoxamine, Decreases Methamphetamine Conditioned Place Preference in Mice
Volume: 9 Issue: 1
Author(s): Y. Takamatsu, H. Yamamoto, Y. Hagino, A. Markou and K. Ikeda
Affiliation:
Keywords: Conditioned place preference, Fluvoxamine, Methamphetamine, Mice, Paroxetine, Serotonin transporter, dopamine transporter, Knoutout mice, Biochemical Down Regulation
Abstract: Monoamine transporters are the main targets of methamphetamine (METH). Recently, we showed that fluoxetine, a selective serotonin reuptake inhibitor (SSRI), decreased METH conditioned place preference (CPP), suggesting that serotonin transporter (SERT) inhibition reduces the rewarding effects of METH. To further test this hypothesis, in the present study we investigated the effects of additional SSRIs, paroxetine and fluvoxamine, on METH CPP in C57BL/6J mice. In the CPP test, pretreatment with 20 mg/kg paroxetine abolished the CPP for METH, whereas pretreatment with 100 mg/kg fluvoxamine prior to administration of METH failed to inhibit METH CPP. These results suggest that paroxetine, a medication widely used to treat depression, may be a useful tool for treating METH dependence. Further, these data suggest that molecules other than the SERT [such as G protein-activated inwardly rectifying K+ (GIRK) channels] whose activities are modulated by paroxetine and fluoxetine, but not by fluvoxamine, are involved in reducing METH CPP by paroxetine and fluoxetine.
Export Options
About this article
Cite this article as:
Takamatsu Y., Yamamoto H., Hagino Y., Markou A. and Ikeda K., The Selective Serotonin Reuptake Inhibitor Paroxetine, but not Fluvoxamine, Decreases Methamphetamine Conditioned Place Preference in Mice, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795017236
DOI https://dx.doi.org/10.2174/157015911795017236 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Effect of Environmental Extremely Low-Frequency Electromagnetic Fields Exposure on Inflammatory Mediators and Serotonin Metabolism in a Human Neuroblastoma Cell Line
CNS & Neurological Disorders - Drug Targets Crocetin, a Carotenoid Derivative, Inhibits VEGF-Induced Angiogenesis via Suppression of p38 Phosphorylation
Current Neurovascular Research Critical Atomic-level Processing Technologies: Remote Plasma-enhanced Atomic Layer Deposition and Atomic Layer Etching
Micro and Nanosystems Beta-blockers in the Perioperative Period: Are there Indications other than Prevention of Cardiac Ischemia?
Current Drug Targets Lipid Membranes and β-Amyloid: A Harmful Connection
Current Protein & Peptide Science Metabotropic Glutamate Receptor 7 (mGluR7) as a Target for Modulating Pain-evoked Activities of Neurons in the Hippocampal CA3 Region of Rats
CNS & Neurological Disorders - Drug Targets Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry Prognostic Significance of Serum Magnesium in Acute Intracerebral Hemorrhage Patients
Current Neurovascular Research Do Histamine receptor 3 antagonists have a place in the therapy for schizophrenia?
Current Pharmaceutical Design Acetylcholine Receptors and Tau Phosphorylation
Current Molecular Medicine Is Intraoperative Opioids Avoidance A Utopia? A Matched Study in Laparoscopic Hysterectomy
Current Reviews in Clinical and Experimental Pharmacology Macrocyclic Lactones in the Treatment and Control of Parasitism in Small Companion Animals
Current Pharmaceutical Biotechnology CCR1 Chemokine Receptor Antagonist
Current Pharmaceutical Design Antidotes for Acute Cyanide Poisoning
Current Pharmaceutical Biotechnology Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry The Developing Utility of Zebrafish Models for Cognitive Enhancers Research
Current Neuropharmacology Angiotensin Mediated Oxidative Stress and Neuroprotective Potential of Antioxidants and AT1 Receptor Blockers
Mini-Reviews in Medicinal Chemistry Psychotropics and Fertility
Current Women`s Health Reviews Regulation of Brain Reward by the Endocannabinoid System: A Critical Review of Behavioral Studies in Animals
Current Pharmaceutical Design The Host Complement System and Arbovirus Pathogenesis
Current Drug Targets